Mirum Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) on August 16, 2021, covering events occurring on August 16 and August 19, 2021. The filing addresses changes to the Company's Board of Directors and related governance appointments.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on corporate governance changes rather than financial performance.
Material Changes
- Director Resignation: Tiba Aynechi, Ph.D., resigned as a director effective August 19, 2021. The resignation was not the result of any dispute with the Company.
- Director Appointment: William Fairey was appointed to the Board effective August 19, 2021, serving as a Class I director with a term expiring at the 2023 Annual Meeting.
- Committee Assignments: Mr. Fairey was appointed to the Audit Committee, succeeding Patrick Heron. Additionally, Carol L. Brosgart, M.D., and Patrick Heron were appointed to the Nominating and Corporate Governance Committee and Compensation Committee, respectively.
Compensation and Governance Details
Mr. Fairey received the following compensation in connection with his appointment:
- Stock Options: An option to purchase 34,000 shares of common stock, vesting in three equal annual installments.
- Cash Retainer: An annual cash retainer of $40,000 for Board service and $10,000 for Audit Committee service, pro-rated for 2021.
- Future Grants: Eligibility for an annual option grant of 17,000 shares commencing with the 2022 Annual Meeting.
Investor Verification Checklist
- Verify the effective date of Tiba Aynechi's resignation and William Fairey's appointment (August 19, 2021).
- Confirm the vesting schedule of the 34,000 stock options granted to Mr. Fairey.
- Review the Company's Non-Employee Director Compensation Policy for details on future annual grants.
- Check for any related person transactions involving the new director, as none were disclosed in this filing.